RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure:Phase I/II

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by West China Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)West China Hospital四川大学华西医院ChengduHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06195189, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory

    Inclusion criterion 3

  3. EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.

    Inclusion criterion 4

  4. Patient must have measurable disease according to RECIST 1.1.

    Inclusion criterion 9

  5. A history of malignant tumors within 2 years.

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06195189, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • To provide a signed and dated, written informed consent.
  • 80≥Age ≥ 18 years old
  • Histologically or cytologically confirmed non-squamous NSCLC with documented EGFR mutations from a local laboratory
  • EGFR-sensitive mutations including exon 19 deletion and exon 21 L858R mutated, and exon 20 T790M mutated.
  • Predicted life expectancy ≥ 12 weeks
  • EGFR-TKI resistance or intolerant to standard EGFR TKIs therapy.
  • No previous systemic chemotherapy for advanced or metastatic disease.
  • Adequate organ system function:
  • Patient must have measurable disease according to RECIST 1.1.
  • Patients with stable or pre-treated brain metastasis (BM) can be enrolled

Exclusion Criteria:

  • Spinal cord compression or meningeal metastasis
  • A history of malignant tumors within 2 years.
  • With known resistant mutations that have approved target therapy
  • Recover from AEs caused by previous treatment
  • A history of stroke or intracranial hemorrhage within 6 months prior to initial dosing.
  • Any severe or poorly controlled systemic disease per investigator's judgment active infections, including but not limited to hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency (HIV)

Quoted from ClinicalTrials.gov, NCT06195189, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06195189, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06195189